Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Source: N Engl J Med 2010; 362:2251-2259

Visit Link

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Source: N Engl J Med 2010; 362:2260-2270

Visit Link

Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study

Source: J Clin Oncol (Meeting Abstracts) June 2010 vol. 28 no. 18_suppl LBA6500

Visit Link

Continued Superiority of Nilotinib vs Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond 1 Year

Source: Haematologica 2010; 95[suppl.2]:459, abs. 1113

Visit Link

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year

Source: J Clin Oncol (Meeting Abstracts) May 2010 vol. 28 no. 15_suppl 6501

Visit Link

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Source: Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 6

Visit Link

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Source: Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 210

Visit Link

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

Source: ASH Annual Meeting 2011; Presentation #602

Visit Link

Updated Phase 1 Data on Ponatinib, a Pan-BCR-ABL Inhibitor, in CML and Other Hematologic Malignancies

Source: ESH-iCMLf 13th International Conference, September 2011

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Source: The Lancet Oncology; Volume 12, Issue 9, September 2011, Pages 841–851

Visit Link

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Source: ASH Annual Meeting 2011; Presentation #207

Visit Link

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Source: ASH Annual Meeting 2011; Presentation #206

Visit Link

Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION

Source: J Clin Oncol (Meeting Abstracts) May 2011 vol. 29 no. 15_suppl 6510

Visit Link

Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial

Source: ASH Annual Meeting 2011; Presentation #2767

Visit Link

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up

Source: J Clin Oncol (Meeting Abstracts) May 2011 vol. 29 no. 15_suppl 6511

Visit Link

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Source: ASH Annual Meeting 2011; Presentation #210

Visit Link

PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

Source: J Clin Oncol 30, 2012 (suppl; abstr 6503)

Visit Link

Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.

Source: J Clin Oncol 30, 2012 (suppl; abstr 6504)

Visit Link

Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.

Source: J Clin Oncol 30, 2012 (suppl; abstr 6505^)

Visit Link

Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).

Source: J Clin Oncol 30, 2012 (suppl; abstr 6509^)

Visit Link

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

Source: Leukemia doi:10.1038/leu.2012.134

Visit Link

RNA Quantitation Platform Comparison: nCounter, RT-qPCR, ddPCR

Conference: Next Generation Dx Summit 2016

View PDF

Oncomine Focus Assay: simultaneous detection of clinically relevant hotspot mutations, CNVs and gene fusions in 52

Conference: AACR Annual Meeting 2016
Abstract: 1397

View PDF

Detection of a Novel RET Gene Fusion in a Non-Small Cell Lung Cancer Patient Using AMP Chemistry

Conference: Fourth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic 2016
Abstract: A16

View PDF

Mutation Profiling of Colorectal Cancer ctDNA Using Ampliseq CHP2 Cancer Panel

Conference: AACR-NCI- EORTC International Meeting 2015
Abstract: A29

View PDF

Oncomine® Cancer Panel: simultaneous detection of clinically relevant hotspot mutations, CNVs and gene fusions in solid tumors

Conference: AACR 2015

View PDF

Liquid Biopsy using the Ion AmpliSeq v2 Cancer Panel

Conference: AACR 2015

View PDF

Development and Validation of a NOTCH Custom NGS Assay for Identifying NOTCH1 Mutations in Chronic Lymphocytic Leukemia and Other Lymphoid Malignancies

Conference: EHA 2014
Abstract: P861

View PDF

Droplet digital PCR A1:C31 of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma

Conference: ASCO 2014

View PDF

Quantitative Assessment of circulating BRAF DNA on stage IV melanoma patients undergoing BRAF inhibitor treatment

Conference: AACR 2014

View PDF

Phasing Analysis of TKI Resistance Mutations in the BCR-ABL1 Kinase Domain and Neighboring Domains Using Next-Generation Sequencing

Conference: ASH 2013
Abstract: 3817

View PDF

Development and Validation of Highly Sensitive MRDx BCR-ABL Test for Monitoring Deep Molecular Response in Patients with Chronic Myeloid Leukemia

Conference: ASH 2013
Abstract: 2617

View PDF

Liquid Biopsy: Analytical Validation of a Plasma-Based BRAF V600 AS-PCR Assay

Conference: SMR 2013

View PDF

FFPE DNA Quality: Impact on Downstream Performance in Molecular Diagnostic Assays

Conference: AMP 2013
Abstract: ID102

View PDF

Obtaining Maximal Information from Limited FFPE Tissue Specimens: Development and Validation of a 4-Gene Custom NGS Panel for a GIST Clinical Trial

Conference: MC13-0069 Markers in Cancer
Abstract: MC13-6009

View PDF

Mutation detection in FFPE and plasma circulating DNA with a focused ALK-EGFR-KRAS Next-Generation Sequencing panel

Conference: AACR-EORTC 2013
Abstract: A208

View PDF

Evaluation of HGF and MET protein expression in NSCLC tumor specimens from patients previously treated with target or chermotherapies

Conference: AACR-EORTC 2013
Abstract: A42

View PDF

Clinical assessment of MUC1 protein expression in FFPE tissue: Development and validation of an immunohistochemistry assay as a predictive assay for response to MUC1 vaccines

Conference: AACR_EORTC 2013
Abstract: B297

View PDF

Analysis of plasma-based BRAF and NRAS mutation detection in patients with stage III and IV melanoma

Conference: ASCO 2013

View PDF

Validation of Illumina TruSeq Amplicon Cancer Panel with Concordance Testing Using Ion AmpliSeq Cancer Panel and Other Methods

Conference: AACR 2013
Abstract: 3229

View PDF

Complementary Analysis of LKB1/STK11 Mutation and Protein Expression Status using Next-Generation Sequencing, Sanger Sequencing and Immunohistochemistry

Conference: AACR 2013
Abstract: 3509

View PDF

Highly Sensitive Detection of EGFR T790M on Ion Torrent PGM

Conference: AACR 2013
Abstract: 3490

View PDF

Absolute Quantification of EGFR Activation and Resistance Mutations by Droplet Digital PCR in Circulating Nucleic Acids

Conference: AACR 2013
Abstract: 3491

View PDF

Clinical Assessment of PTEN mutation in FFPE Tissue: Comparison of Sanger Sequencing, Immunohistochemistry and Chomogenic In Situ Hybridization Methods

Conference: AACR 2013
Abstract: 39

View PDF

Non-Invasive Absolute Quantification of EGFR Activating Mutation L858R and Gatekeeper Mutation T790M in NSCLC Plasma Samples Using Droplet Digital PCR

Conference: EORTC 2012
Abstract: 450

View PDF

QX100 ddPCR Assay Development and Optimization for EGFR T790M Mutation: Identification in CNAs

Conference: Biorad 2012

View PDF

Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance

Conference: ASH 2012
Abstract: 2549

View PDF

Analytical Validation of Ion AmpliSeq Cancer Panel 2.0

Conference: AMP 2012

View PDF

Liquid Biopsy: the Application of Allele-Specific PCR (AS-PCR) and Mutation-Directed SNaPshot Assay to Detect BRAF and NRAS Mutant DNA in Peripheral Blood from Metastatic Melanoma Patients

Conference: AMP 2012
Abstract: ST57

View PDF

Beyond V600E: Comprehensive genotyping of BRAF codon 600

Conference: AMP 2011

View PDF

Molecular Oncology 10 (2016) 157-165

Blood (ASH Annual Meeting Abstracts) 2013(21)

Abstract: 652

Visit Link

Mol Cancer Ther 2013 May;12(5):632-42. doi: 10.1158/1535-7163.MCT-12-0999. Epub 2013 Feb 26.

Blood (ASH Annual Meeting Abstracts) 2012 120(21)

Abstract: 3747

Visit Link

Blood (ASH Annual Meeting Abstracts) 2012 120(21)

Abstract: 163

Visit Link

Blood (ASH Annual Meeting Abstracts) 2012 120(21)

Abstract: 3749

Visit Link

Blood (ASH Annual Meeting Abstracts) 2012 120(21)

Abstract: 915

Visit Link

Blood (ASH Annual Meeting Abstracts) 2012 120(21)

Abstract: 3763

Visit Link

Blood 2011 118: 5250-5254

Abstract: 5250

Visit Link

Blood (ASH Annual Meeting Abstracts) 2011 118(21)

Abstract: 109

Visit Link

Journal of Molecular Diagnostics 2007, Vol 9, No. 5

Abstract: H23

Visit Link

Blood (ASH Annual Meeting Abstracts) 2007 110(11)

Abstract: 2939

Visit Link

First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Sep 12-15, 2006

Abstract: B68

Visit Link